Hepatitis B Virus
CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
Published in Virus Weekly, October 2nd, 2007
CEL-SCI Corporation (AMEX:CVM) announces that its CEL-1000 immunomodulator was shown to be able to jump start the immune response against the recombinant hepatitis B virus protein more quickly than did other vaccine adjuvants. This effect in the mouse model was seen within 14 days, most pronounced with a single dose of CEL-1000 at day 0 and resulted in up to a 40% increase in antibody signal at day 28. Also, the timing of the CEL-1000 administration had significant impact on the type of immune response that was created, as well as its strength.
The significance of this data lies in the fact that CEL-1000 appears to be able to mount a faster immune response, something...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
Source: Virus Weekly (2007-10-02)
More Articles from Virus Weekly
- Cancer Gene Therapy
T vs. B: Re-engineered Human T Cells Effectively Target and Kill Cancerous B Cells - Cancer Vaccines
M.D. Anderson-led team reports possible key to autoimmune disease - Chronic Fatigue Syndrome
Chronic fatigue syndrome linked to stomach virus - Enzyme Research
Scientists learn structure of enzyme in unusual virus - Nanotechnology
Scientists reveal DNA-enzyme interaction with first ever real time footage - Type 1 Diabetes
Immune police recognize good and bad guys in the body - More from this issue of Virus Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
